Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
about
Cancer pharmacogenomics: strategies and challengesClinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosingCancer pharmacogenomics, challenges in implementation, and patient-focused perspectivesImpact of New Genomic Technologies on Understanding Adverse Drug ReactionsCan knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigmUsing germline genomics to individualize pediatric cancer treatmentsMercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fictionThe human ITPA polymorphic variant P32T is destabilized by the unpacking of the hydrophobic corePharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical UsePersonalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicineChildhood Acute Lymphoblastic Leukemia: Progress Through CollaborationNUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicityDrug methylation in cancer therapy: lessons from the TPMT polymorphismHuman thiopurine methyltransferase activity varies with red blood cell agePharmacogenomic discovery using cell-based modelsPolymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies.Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activityPrevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine modelImputation of TPMT defective alleles for the identification of patients with high-risk phenotypesLong-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment responseFunctional analysis of human microsomal epoxide hydrolase genetic variants.Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.Thiopurine methyltransferase predicts the extent of cytotoxicty and DNA damage in astroglial cells after thioguanine exposure.Teratogen update: azathioprine and 6-mercaptopurine.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.The potential and limitations of personalised medicine in primary care.Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.Azathioprine for atopic dermatitis.Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan.Negative energy balance and hepatic gene expression patterns in high-yielding dairy cows during the early postpartum period: a global approach.Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia.Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose.Identifying genomic and developmental causes of adverse drug reactions in children.Biology of childhood acute lymphoblastic leukemia.Candidate gene approach for pharmacogenetic studies.
P2860
Q24289309-1AB1EEA6-7460-4469-95C6-0A59DACE044AQ24632749-F4530FAD-B56B-44AB-94B1-43B2D7F995C0Q26741009-A77A1870-58AF-46F4-817B-3D524C465367Q26787099-50230E95-70F3-41CD-A130-10B22A3CAB7DQ26859144-ED1EFBBC-201E-4CDD-85B5-57F529062601Q26866379-B3BFA07A-36E0-4C54-B86B-7B748E3110FCQ27003261-50840CE7-652A-4315-ADD1-D0677ABE6901Q27023839-69B76142-E786-4DAC-93BA-14579D263B03Q27677053-F5DECDE5-B932-4947-AF27-1BBC32936AABQ28068930-99B0F036-4998-443B-8F52-239E35C87AB6Q28082746-6BE215AC-18A7-485F-9688-0319ABAF685DQ28087637-5989F0F9-CAEF-481C-A833-7F63AF51EC99Q28115755-288EB9CF-BDB9-4945-8AD7-50471E4D677AQ28212325-67F5834D-9CBA-467C-86F2-5577B9FF9349Q28365897-F9435B07-853A-44DC-B5D3-B4A8CAFFDEFFQ28392982-3785C930-6C26-4DE4-9544-3FAF2EF06A37Q30244222-C3DDFBD1-81B7-4583-9B79-31124C2D893EQ33394134-F9BD4593-C4CE-4303-882A-C67AA7A83D6AQ33418418-CF518614-D1FD-4B51-926C-9FEECA7766EFQ33576773-5843D53C-97F9-480D-83AD-3AADD442E45FQ33603164-0D7F8322-8D00-4F1F-A486-8D91517CC596Q33633953-78B8A8C6-2E02-486B-8B02-D40AF58D4357Q33645862-689663B5-DBC6-4C51-9A76-574FC2A5C857Q33674158-29C3FA1B-FD08-44F0-A2BD-825A67384A15Q33881654-03DCFB0E-0F66-4CB1-838B-87C127050EF9Q34026161-A5CBED34-A89B-45E1-9D46-51539A6D179DQ34117269-974BF690-1FD6-4D7B-B262-13833B06E0C0Q34124884-A36C7CA7-613D-4FFB-9CB1-7721D55B309BQ34131354-A417F75A-40C4-4086-906F-A7FE4F49CF41Q34224448-EAB23AA8-A49D-4490-83A3-1ACF3788B4CAQ34315833-CE23D211-8581-4431-8838-0F1F48114084Q34328070-F3D607C0-A04B-400D-81B0-5E2C3EA128AFQ34343197-EA01C052-460C-4183-8113-83207543CCB5Q34432736-88006388-B62B-4DF8-AEA8-779893D599E2Q34459885-C7915B50-9753-45E1-9D5B-39F38F92A71FQ34478851-FEA80909-BA7D-427D-A815-B1207554AFE1Q34549324-EE25600F-9391-40BB-B15D-A546F4397F74Q34603032-57411262-03B4-49E7-B121-AB81C71B4BF2Q34605953-1F1E443F-B2A9-495B-B085-CA2533580F19Q34609133-6285DA03-26D9-4210-AEA1-2694F280BB31
P2860
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Mercaptopurine therapy intoler ...... -methyltransferase gene locus.
@ast
Mercaptopurine therapy intoler ...... -methyltransferase gene locus.
@en
type
label
Mercaptopurine therapy intoler ...... -methyltransferase gene locus.
@ast
Mercaptopurine therapy intoler ...... -methyltransferase gene locus.
@en
prefLabel
Mercaptopurine therapy intoler ...... -methyltransferase gene locus.
@ast
Mercaptopurine therapy intoler ...... -methyltransferase gene locus.
@en
P2093
P356
P1476
Mercaptopurine therapy intoler ...... -methyltransferase gene locus.
@en
P2093
Hancock ML
Krynetski EY
Relling MV
Ribeiro RC
Sandlund JT
P304
P356
10.1093/JNCI/91.23.2001
P407
P577
1999-12-01T00:00:00Z